vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $75.1M, roughly 1.7× SAUL CENTERS, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 10.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 6.2%).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
BFS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $129.7M |
| Net Profit | $6.5M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 65.4% | -25.0% |
| Net Margin | 8.7% | — |
| Revenue YoY | 10.6% | 73.4% |
| Net Profit YoY | -19.6% | — |
| EPS (diluted) | $0.15 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $129.7M | ||
| Q3 25 | $72.0M | $164.9M | ||
| Q2 25 | $70.8M | $114.4M | ||
| Q1 25 | $71.9M | $81.7M | ||
| Q4 24 | $67.9M | $74.8M | ||
| Q3 24 | $67.3M | $62.9M | ||
| Q2 24 | $66.9M | $54.1M | ||
| Q1 24 | $66.7M | $41.4M |
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $25.7M | ||
| Q2 25 | $10.7M | $-12.8M | ||
| Q1 25 | $9.8M | $-41.2M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | $-54.8M | ||
| Q2 24 | $14.4M | $-70.4M | ||
| Q1 24 | $13.6M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | 73.6% | 97.4% | ||
| Q2 24 | 74.2% | 96.2% | ||
| Q1 24 | 72.8% | 96.4% |
| Q4 25 | 65.4% | -25.0% | ||
| Q3 25 | 69.1% | 15.1% | ||
| Q2 25 | 68.7% | -11.1% | ||
| Q1 25 | 66.5% | -52.2% | ||
| Q4 24 | 82.9% | -81.2% | ||
| Q3 24 | 72.8% | -89.3% | ||
| Q2 24 | 75.0% | -125.1% | ||
| Q1 24 | 72.4% | -336.5% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | 15.6% | ||
| Q2 25 | 15.1% | -11.1% | ||
| Q1 25 | 13.6% | -50.4% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | -87.1% | ||
| Q2 24 | 21.6% | -130.1% | ||
| Q1 24 | 20.4% | -328.9% |
| Q4 25 | $0.15 | $0.04 | ||
| Q3 25 | $0.32 | $0.28 | ||
| Q2 25 | $0.33 | $-0.14 | ||
| Q1 25 | $0.29 | $-0.47 | ||
| Q4 24 | $0.22 | $-0.71 | ||
| Q3 24 | $0.48 | $-0.70 | ||
| Q2 24 | $0.48 | $-0.91 | ||
| Q1 24 | $0.45 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $93.0M |
| Total DebtLower is stronger | $468.4M | — |
| Stockholders' EquityBook value | $307.8M | $114.8M |
| Total Assets | $2.2B | $605.2M |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | $93.0M | ||
| Q3 25 | $11.8M | $110.9M | ||
| Q2 25 | $5.3M | $75.2M | ||
| Q1 25 | $6.5M | $61.9M | ||
| Q4 24 | $10.3M | $58.5M | ||
| Q3 24 | $7.2M | $36.4M | ||
| Q2 24 | $6.9M | $32.3M | ||
| Q1 24 | $7.1M | $43.3M |
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $307.8M | $114.8M | ||
| Q3 25 | $316.6M | $73.6M | ||
| Q2 25 | $322.4M | $32.7M | ||
| Q1 25 | $328.4M | $32.8M | ||
| Q4 24 | $335.8M | $59.1M | ||
| Q3 24 | $341.8M | $-30.5M | ||
| Q2 24 | $345.7M | $15.1M | ||
| Q1 24 | $347.1M | $74.1M |
| Q4 25 | $2.2B | $605.2M | ||
| Q3 25 | $2.2B | $538.6M | ||
| Q2 25 | $2.1B | $555.3M | ||
| Q1 25 | $2.1B | $548.8M | ||
| Q4 24 | $2.1B | $594.1M | ||
| Q3 24 | $2.1B | $504.4M | ||
| Q2 24 | $2.1B | $551.1M | ||
| Q1 24 | $2.0B | $663.5M |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 15.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | $60.7M | ||
| Q3 25 | $20.6M | $14.3M | ||
| Q2 25 | $26.6M | $5.0M | ||
| Q1 25 | $30.4M | $-42.2M | ||
| Q4 24 | $121.2M | $-35.7M | ||
| Q3 24 | $26.5M | $-42.5M | ||
| Q2 24 | $32.1M | $-40.2M | ||
| Q1 24 | $33.8M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.3M | — | ||
| Q2 24 | $-12.5M | $-40.3M | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.1% | — | ||
| Q2 24 | -18.7% | -74.5% | ||
| Q1 24 | -17.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 81.5% | 0.0% | ||
| Q2 24 | 66.7% | 0.2% | ||
| Q1 24 | 68.3% | 0.0% |
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | 0.56× | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
